Lenacapavir: Hope, Hype and a Price Tag That Hurts

Lenacapavir is the name on everyone’s lips at the World AIDS Conference in Rio de Janeiro: a long‑acting HIV prevention shot that works like a twice‑yearly vaccine and could radically slow down new infections. With one injection protecting you for six months, it’s a game‑changer for people who struggle with daily pills, stigma, or unstable access to healthcare. But behind the scientific excitement, the pharmaceutical company Gilead is asking eye‑watering prices and tightly controlling who gets access. For queer communities in Belgium and beyond, this tension between medical progress and economic injustice is impossible to ignore.

What Is Lenacapavir, Exactly?
Lenacapavir is a new antiretroviral that targets the HIV capsid, the protein shell that protects the virus’s genetic material. By destabilising that shell, lenacapavir blocks several key steps in the HIV life cycle and stops the virus from multiplying and spreading in the body.

The drug can be used both as treatment for people already living with HIV and as pre‑exposure prophylaxis (PrEP) for those at higher risk. After an initial short oral phase, lenacapavir is given as a subcutaneous injection every six months, which means two doses a year instead of daily tablets. Clinical data suggest a dramatic reduction in new infections – up to 99.9% risk reduction in some prevention studies – making it one of the most promising tools in the fight against HIV today.

A Game‑Changer for Queer Health
For many LGBTQIA+ people, HIV prevention is not just about individual behaviour; it’s about how accessible, realistic and stigma‑free the tools are. Long‑acting PrEP like lenacapavir could be particularly important for:

People who can’t or don’t want to take a pill every day (because of mental health, chaotic schedules, fear of being “outed” by their medication, or unstable housing).

Communities facing ongoing stigma in health systems, where every clinic visit can feel like a hurdle.

Younger queer and trans people who might engage in higher‑risk behaviour but don’t have regular contact with medical services.

With one injection offering six months of protection, lenacapavir could make prevention more discreet, less tied to daily discipline, and easier to integrate into queer lives that are not always “clinic‑friendly”. It also has the potential to reduce new infections in regions where health infrastructures are fragile, which matters deeply for queer communities in the global South.

When Progress Meets a Paywall
The problem: while activists talk about “revolution”, Gilead’s business model looks more like a wall. At the Rio conference, Médecins Sans Frontières and other actors called out the company for keeping prices sky‑high and restricting licences. In the United States, lenacapavir is marketed at around 28,000 dollars per person per year for HIV treatment, while estimates show it could be produced for less than 40 dollars.

Generic manufacturers are being allowed to produce cheaper versions for some low‑income countries, but these licences exclude many middle‑income states, especially those where HIV prevalence is high and queer people are heavily impacted. MSF’s demand in Rio is simple: make lenacapavir available in all low‑ and middle‑income countries at a price not exceeding 40 dollars per person per year. For now, Gilead decides who gets access, on which continent, and under which conditions — a power dynamic that feels disturbingly familiar in the history of HIV.

For queer communities, this is not an abstract debate: it’s about whether your life and health are treated as a human right or a luxury good.

Why Brussels and Belgium Should Care
Belgium sits in a strange position: a well‑resourced health system, strong HIV expertise, but queer people who still experience stigma, unequal access, and gaps in prevention. Daily oral PrEP is available and effective, yet uptake is uneven, and the most vulnerable — migrants, trans people, those in precarious situations — often struggle to navigate the system.

Lenacapavir could change the landscape here too: fewer appointments, fewer pills, a more discreet form of protection that could work better for people who don’t fit the “ideal PrEP user” profile. But if prices remain in the tens of thousands of euros per year, health systems will ration access, insurance models will be strained, and people with less social capital risk being left behind. The promise of a “six‑month HIV shield” only means something if it’s actually reachable from Brussels, Liège or Charleroi — not just in conference speeches in Rio.

Queer Politics of Access
For Ket’s audience, the story around lenacapavir is also a story about queer politics: who gets included in progress, and who gets pushed to the margins. It raises several key questions:

Representation: scientific breakthroughs are inspiring, but they need to be rooted in the realities of those most affected — including queer and trans people of colour, sex workers, migrants, and people who use drugs.

Intersectionality: HIV does not hit everyone equally, and access barriers pile up when someone is poor, racialised, gender‑nonconforming or living in a hostile legal environment.

Safer spaces: prevention only works if people feel safe enough to show up, ask questions, and get the care they need without judgment. A miracle injection doesn’t erase stigma on its own.

Lenacapavir is important for LGBTQIA+ people today because it shows how close we are to ending the HIV epidemic — and how quickly that dream can slip away if corporate interests and political disinvestment win.

Practical Info
Name: Lenacapavir (commercial name in some countries: Sunlenca®).

Use: Long‑acting antiretroviral for HIV treatment and prevention (PrEP), administered by injection every six months after an initial oral phase.

Conference: Highlight of the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, where activists and organisations like MSF demanded fair pricing and global access.

Access: Currently approved in parts of Europe, North America and elsewhere; generic deals are in progress but limited to certain low‑income countries. Actual availability and cost in Belgium depend on national negotiations and reimbursement decisions.

If you’re in Belgium and interested in HIV prevention options, talk to an HIV clinic or sexual health centre for up‑to‑date information on PrEP and on how new tools like lenacapavir might be integrated in the coming years.

A six‑month shot that can almost stop HIV transmission sounds like science fiction turned real — the next step is making sure it doesn’t become a privilege reserved for the few.

KET Magazine is a community‑driven, non‑profit magazine run by volunteers and based in Brussels. You can find our other music and nightlife stories on ket.brussels, and you can always write to us to share your projects or pitch a story: info@ket.brussels